


immunoterapi

Kanser hücrelerinin konak savunma sisteminden kaçışı...




İmmunoterapi & Kanser



CTLA-4 & PD-1/L1

Kontrol noktası (Checkpoint) Blokajı





CTLA-4 :

Bağıışıklık yanıtının oluşmasında fren pedalı



Antigen-MHC : TCR



Gaz pedalı
B7 : CD28


İPİLİMUMAB (YERVOY)



Fren Pedalı
B7 : CTLA-4






PD-L1 Kontrol Noktası: Bağışıklık sistemine saldırı sırasında ilk savunma hattı





**TEDAVİ
ÖNCESİ**





**TEDAVİ
SONRASI**





Tedaviye Dirençli Melanomlu Hastada Anti PD-1 Tedavi ile Sonuç

BBaşlangıç: 13 Nisan, 2012



9 Nisan, 2013









Yanıt Deęerlendirme

**TEDAVİ
ÖNCESİ**



**TEDAVİ
8. HAFTA**

**TEDAVİ
16. HAFTA**





Özel Genetik Alt-Tip ve Tedavi Yanıt İlişkisi

**BAĞIRSAK
KANSERİ**



**KOLANJİO
KARSİNOM**



**TEDAVİ
ÖNCESİ**

**TEDAVİ 20.
HAFTA**

Kanserde İmmunoterapi Konusunda Gelecek Hedefler

